Drug Combination Details
| General Information of the Combination (ID: C07164) | |||||
|---|---|---|---|---|---|
| Name | Sanguinarine NP Info | + | Cisplatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vitro Model | A2780/S | CVCL_4863 | Ovarian endometrioid adenocarcinoma | Homo sapiens | ||
| A2780/R | CVCL_4862 | Ovarian endometrioid adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Sanguinarine reversed cisplatin resistance in A2780/R cells through intracellular GSH depletion. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Sanguinarine enhances cisplatin sensitivity via glutathione depletion in cisplatin-resistant ovarian cancer (A2780) cells. Chem Biol Drug Des. 2020 Feb;95(2):215-223. | |||
